Cited 8 times in
Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김경식 | - |
dc.contributor.author | 한소정 | - |
dc.date.accessioned | 2022-12-22T01:59:28Z | - |
dc.date.available | 2022-12-22T01:59:28Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191412 | - |
dc.description.abstract | Purpose: To assess the expression levels of YAP and TAZ in patient-derived HCC tissue and identify the effects of YAP/TAZ inhibition depending on the baseline YAP/TAZ expression when combined with sorafenib using a patient-derived multicellular tumor spheroid (MCTS) model. Methods: Primary HCC cell lines were established from patient-derived tissue. Six patient-derived HCC cell lines were selected according to YAP/TAZ expression on Western blot: high, medium, low. Then, MCTS was generated by mixing patient-derived HCC cells and stroma cells (LX2, WI38, and HUVECs) and YAP/TAZ expression was assessed using Western blot. Cell viability of MCTS upon 48 h of drug treatment (sorafenib, sorafenib with CA3 0.1 µM, and CA3 (novel YAP1 inhibitor)) was analyzed. Results: Out of six patient-derived HCC cell lines, cell lines with high YAP/TAZ expression at the MCTS level responded more sensitively to the combination therapy (Sorafenib + CA3 0.1 μM) despite the potent cytotoxic effect of CA3 exhibited in all of the patient-derived HCCs. Conclusion: Targeting YAP/TAZ inhibition using the novel YAP1 inhibitor CA3 could be a promising therapeutic strategy to enhance sensitivity to sorafenib especially in HCCs with high YAP/TAZ expression in MCTS. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sojung Han | - |
dc.contributor.googleauthor | Ji Yeon Lim | - |
dc.contributor.googleauthor | Kyungjoo Cho | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Simon Weonsang Ro | - |
dc.contributor.googleauthor | Kyung Sik Kim | - |
dc.contributor.googleauthor | Haeng Ran Seo | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.identifier.doi | 10.3390/cancers14112733 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00299 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 35681712 | - |
dc.subject.keyword | CA3 | - |
dc.subject.keyword | TAZ | - |
dc.subject.keyword | YAP | - |
dc.subject.keyword | hepatocellular carcinoma (HCC) | - |
dc.subject.keyword | multicellular tumor spheroids (MCTS) | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김경식 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2733 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.14(11) : 2733, 2022-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.